SCHEMBL6463083

SCHEMBL6463083

NC(=O)Cc1c(Cl)ccc(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.43
CYP3A4 P08684 2/20 0.43
MAPK1 P28482 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
HTR1A P08908 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
MAOA P21397 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
CYP2C19 P33261 1/20 0.43
ADRA1A P35348 1/20 0.43
DRD3 P35462 1/20 0.43
OPRK1 P41145 1/20 0.43
HTR2B P41595 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6927140 0.98 ADRA2A (0.44) ADRA2ACYP3A4MAPK1KMT2AMEN1
SCHEMBL6017700 0.81 CAPN1 (0.40) ADRA2ACYP3A4MAPK1KMT2AMEN1
SCHEMBL1395814 0.80 AKR1B1 (0.65) ADRA2ACYP3A4MAPK1KMT2AMEN1
SCHEMBL55504 0.80 AKR1B1 (0.65) ADRA2ACYP3A4MAPK1KMT2AMEN1
SCHEMBL11832033 0.80 AKR1B1 (0.43) ADRA2ACYP3A4MAPK1KMT2AMEN1
SCHEMBL1701239 0.80 AKR1B1 (0.65) ADRA2ACYP3A4MAPK1KMT2AMEN1
SCHEMBL29397431 0.80 AKR1B1 (0.65) ADRA2ACYP3A4MAPK1KMT2AMEN1
Hydrochloric Acid SCHEMBL5297667 0.78 ADRA2A (0.65) ADRA2ACYP3A4MAPK1KMT2AMEN1
Ammonia Solution, Strong SCHEMBL25360718 0.78 AKR1B1 (0.63) ADRA2ACYP3A4MAPK1KMT2AMEN1
Hydrochloric Acid SCHEMBL29008321 0.78 AKR1B1 (0.63) ADRA2ACYP2C9HSD17B10AKR1B1GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
US-4627874-A RICE PRODUCTION IDEMITSU KOSAN COMPANY LIMITED (JP) 1986-12-09 US disclosed
US-4502883-A CONTAINING CHLORINE IDEMITSU KOSAN COMPANY LIMITED (JP) 1985-03-05 US disclosed
US-4455164-A HALOGENATED DERIVATIVES IDEMITSU KOSAN COMPANY LIMITED (JP) 1984-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 ADRA2A 117/4885CYP3A4 284/4885MAPK1 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.